Clinical Trials Logo

Advanced/Metastatic Solid Tumors clinical trials

View clinical trials related to Advanced/Metastatic Solid Tumors.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02444793 Terminated - Clinical trials for Advanced/Metastatic Solid Tumors

A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors

Start date: May 2015
Phase: Phase 1
Study type: Interventional

This study is a Phase 1b, open label, multi center, multi-dose trial designed to estimate the maximum tolerated dose (MTD) and select the recommended dose for phase 2 (RP2D) investigations of PF- 05082566 in combination with KW-0761 (mogamulizumab) in patients with advanced solid tumors. Once the MTD of PF-05082566 administered in combination with KW-0761 is estimated (dose finding), one or more expansion cohorts of patients with selected advanced solid tumors (dose-expansion ) will be enrolled to further characterize the combination in term of safety profile, anti tumor activity, pharmacokinetics, pharmacodynamics and biomarkers modulation.

NCT ID: NCT01092052 Terminated - Clinical trials for Advanced/Metastatic Solid Tumors

Study of NMS-1116354 in Advanced/Metastatic Solid Tumors

Start date: January 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety profile of NMS-1116354, a CDC7 kinase inhibitor, in adult patients with advanced/metastatic solid tumors.

NCT ID: NCT00996255 Terminated - Clinical trials for Advanced/Metastatic Solid Tumors

Dose-Escalation Study of PHA-793887 in Patients With Advanced/Metastatic Solid Tumors

Start date: November 2006
Phase: Phase 1
Study type: Interventional

The purpose of this open-label, multi center, phase I study, was to determine the safety profile of PHA-793887 administered by intravenous infusion to patients with advanced/metastatic solid tumors. This was a dose-finding study to determine the maximum tolerated dose and the dose of PHA-793887 that can be safely used in phase II investigations.